Torrent Pharma Results

Led by an 18% y-o-y growth in the domestic formulations segment, which accounts for over half its overall revenues, the company posted 16% growth at a consolidated level

The company exhibited a 2.66 per cent increase in revenue and was able to turn around the PAT by 2.09 per cent

Brazil revenues for the quarter came in at Rs 185 crore, up by 19 percent. US revenues for the quarter were Rs 292 crore, up by 3 percent. Germany revenue was down 12 percent to Rs 220 crore

First major acquisition by Aman Mehta after taking charge at Torrent Pharma in August

Drug firm Torrent Pharma reported a 3.18 per cent rise in its consolidated net profit to Rs 324 crore for the quarter ended March 31, 2021

India revenues grew 7% to stand at Rs 930 cr. Company's consolidated total revenue from operations fell marginally by under 1% to Rs 2,003 cr in Q3FY21

The firm reported an 18.32 per cent rise in its consolidated net profit to Rs 297 crore for the quarter ended in December.

Domestic and US market revenues more or less flat, 20% drop in Brazilian revenues

The company saw its total consolidated revenue in Q4FY20 at Rs 1961 crore, up by a marginal 4.69 per cent over Rs 1873 crore in Q4FY19

US business down by 22% in third quarter, India revenues grow by 5%

The company had witnessed a PBT of Rs 501.87 crore in the corresponding quarter last year on a consolidated basis

Ahmedabad based Pharmaceuticals major, Torrent Pharmaceuticals Limited has posted a 35 per cent year on year (YoY) dip in net profit for the quarter ended June 30, 2017 as its revenues too dipped by 11.4 per centFor the first quarter of the current fiscal, Torrent Pharmaceuticals posted revenues of Rs 1374 crore as against Rs. 1,551 crores during the same period last year. EBIDTA for Q1FY18 was at Rs. 400 crore as against Rs. 462 crore during the same period last year. Profit after tax (PAT) for Q1FY18 was at Rs. 188 crore as against Rs.292 crore during the same period last year. The company said that the previous period include exceptional revenues and profits which was primarily on account of the launch of a new product in US market, which had limited competition. Research and development (R&D) spend during the Q1 FY 2017-18 was Rs 101 crore as against Rs 90 crore during the same period last year. The domestic formulation business recorded revenues of Rs. 464 crore for .